Cantor Fitzgerald Comments on Cytokinetics FY2025 Earnings
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...
Zacks.com on MSN19h
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Astria Therapeutics Receives Buy Rating Due to Promising Clinical Developments and Strategic Market Positioning
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), with ...
Guggenheim raises Immunovant stock target to $46, maintains Buy
Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
Paycor HCM (NASDAQ:PYCR) Given Underweight Rating at JPMorgan Chase & Co.
Paycor HCM (NASDAQ:PYCR – Get Free Report)‘s stock had its “underweight” rating reaffirmed by JPMorgan Chase & Co. in a ...
Elevance Health Posts Q4 Profit Despite Medicaid Drop, Rising Costs; Hikes Dividend 5%
Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.